Integrated genomic profiling, therapy response, and survival in adult acute myelogenous leukemia.

ABSTRACT:

Purpose

Recurrent gene mutations, chromosomal translocations, and acquired genomic copy number aberrations (aCNA) have been variously associated with acute myelogenous leukemia (AML) patient outcome. However, knowledge of the co-occurrence of such lesions and the relative influence of different types of genomic alterations on clinical outcomes in AML is still evolving.

Experimental design

We performed SNP 6.0 array-based genomic profiling of aCNA/copy neutral loss-of-heterozygosity (cnLOH) along with sequence analysis of 13 commonly mutated genes on purified leukemic blast DNA from 156 prospectively enrolled non-FAB-M3 AML patients across the clinical spectrum of de novo, secondary, and therapy-related AML.

Results

TP53 and RUNX1 mutations are strongly associated with

SUBMITTER: Parkin B 

PROVIDER: S-EPMC4417381 | biostudies-literature | 2015 May

REPOSITORIES: biostudies-literature